JP2023529203A5 - - Google Patents
Info
- Publication number
- JP2023529203A5 JP2023529203A5 JP2022575936A JP2022575936A JP2023529203A5 JP 2023529203 A5 JP2023529203 A5 JP 2023529203A5 JP 2022575936 A JP2022575936 A JP 2022575936A JP 2022575936 A JP2022575936 A JP 2022575936A JP 2023529203 A5 JP2023529203 A5 JP 2023529203A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- antigen
- binding polypeptide
- fab
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038075P | 2020-06-11 | 2020-06-11 | |
| US63/038,075 | 2020-06-11 | ||
| US202163151591P | 2021-02-19 | 2021-02-19 | |
| US63/151,591 | 2021-02-19 | ||
| PCT/US2021/036878 WO2021252803A1 (en) | 2020-06-11 | 2021-06-10 | Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529203A JP2023529203A (ja) | 2023-07-07 |
| JP2023529203A5 true JP2023529203A5 (https=) | 2024-06-18 |
Family
ID=76744974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575936A Pending JP2023529203A (ja) | 2020-06-11 | 2021-06-10 | ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240059755A1 (https=) |
| EP (1) | EP4164693A1 (https=) |
| JP (1) | JP2023529203A (https=) |
| KR (1) | KR20230023727A (https=) |
| CN (1) | CN115803063A (https=) |
| AU (1) | AU2021289738A1 (https=) |
| BR (1) | BR112022025227A2 (https=) |
| CA (1) | CA3183808A1 (https=) |
| IL (1) | IL298878A (https=) |
| MX (1) | MX2022015651A (https=) |
| TW (1) | TW202214307A (https=) |
| WO (1) | WO2021252803A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023269666A1 (en) * | 2022-05-13 | 2024-11-28 | Kisbee Therapeutics, Inc. | Apoe lipoprotein systems |
| CN121358763A (zh) * | 2023-06-15 | 2026-01-16 | Rnagene公司 | 包括载脂蛋白质或其片段的融合蛋白质和其用途 |
| CN121293315A (zh) * | 2025-09-26 | 2026-01-09 | 南开大学 | 纳米磷脂盘中bcma全长受体的构建方法及应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2008141230A1 (en) | 2007-05-09 | 2008-11-20 | Lawrence Livermore National Security, Llc | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
| US8883729B2 (en) | 2008-05-22 | 2014-11-11 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles and related compositions, methods and systems |
| EP2890389A1 (en) | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| WO2017035326A1 (en) | 2015-08-25 | 2017-03-02 | Lawrence Livermore National Security, Llc | Stable nanolipoprotein particles and related compositions methods and systems |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| WO2017155837A1 (en) | 2016-03-07 | 2017-09-14 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles and related compositions methods and systems for improved drug loading |
| US12083223B2 (en) | 2017-05-02 | 2024-09-10 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles and related compositions methods and systems for loading RNA |
| US11491215B2 (en) * | 2018-05-24 | 2022-11-08 | Lawrence Livermore National Security, Llc | Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems |
-
2021
- 2021-06-10 MX MX2022015651A patent/MX2022015651A/es unknown
- 2021-06-10 BR BR112022025227A patent/BR112022025227A2/pt unknown
- 2021-06-10 CN CN202180041049.XA patent/CN115803063A/zh active Pending
- 2021-06-10 CA CA3183808A patent/CA3183808A1/en active Pending
- 2021-06-10 IL IL298878A patent/IL298878A/en unknown
- 2021-06-10 WO PCT/US2021/036878 patent/WO2021252803A1/en not_active Ceased
- 2021-06-10 AU AU2021289738A patent/AU2021289738A1/en active Pending
- 2021-06-10 EP EP21737294.5A patent/EP4164693A1/en active Pending
- 2021-06-10 KR KR1020237000866A patent/KR20230023727A/ko active Pending
- 2021-06-10 JP JP2022575936A patent/JP2023529203A/ja active Pending
- 2021-06-11 TW TW110121471A patent/TW202214307A/zh unknown
-
2022
- 2022-12-09 US US18/078,556 patent/US20240059755A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529203A5 (https=) | ||
| JP2023093756A (ja) | 脂質ナノ粒子の生成方法 | |
| CA2922670C (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| CN113271926A (zh) | 脂质纳米颗粒的制备及其施用方法 | |
| JP2021100929A (ja) | 高純度および優れた収率の正確に折り畳まれたエタネルセプト | |
| IL302770A (en) | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines | |
| JP2018115220A (ja) | ｍＲＮＡによってコードされる抗体を送達するための方法及び組成物 | |
| CN105294859A (zh) | 脂蛋白复合物及其制备和用途 | |
| JP2017504568A5 (https=) | ||
| AU2018269304B2 (en) | Preparation of biologically active complexes | |
| JP2020534255A (ja) | 治療用タンパク質の凍結乾燥医薬配合物のためのプロセス | |
| JP6416838B2 (ja) | ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法 | |
| RS60181B1 (sr) | Terapeutska upotreba morfogenetskih proteina kosti | |
| JP2021526505A5 (https=) | ||
| CN103108626A (zh) | 四连蛋白-载脂蛋白a-i、含有它的脂质颗粒及它的用途 | |
| US20250041394A1 (en) | Immunostimulatory mrna compositions and uses thereof | |
| CN107325168B (zh) | 一种经修饰的生长分化因子及其制备方法和应用 | |
| CN105816885A (zh) | 一种药物白蛋白纳米粒的制备及其应用方法 | |
| Kawaguchi et al. | Finding ways into the cytosol: Peptide-mediated approaches for delivering proteins into cells | |
| TW202214307A (zh) | 奈米脂蛋白－多肽結合物及組成物、系統及其使用方法 | |
| CN102205114A (zh) | 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用 | |
| JP2026001029A (ja) | がん治療のための化学療法剤とα－ラクトアルブミン－オレイン酸複合体の組合せ | |
| JP6014241B2 (ja) | ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法 | |
| KR20230034334A (ko) | 개선된 반감기를 갖는 세포외 소포 | |
| TWI825397B (zh) | 包含il-2蛋白及cd80蛋白的融合蛋白調配物 |